Using metronidazole injections to treat skin lesions from leishmaniasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of intralesional metronidazole 0.5% solution as a treatment for cutaneous leishmaniasis. In an open-label, single-arm design, patients with one or more lesions will receive weekly injections of metronidazole directly into the lesions for up to six weeks. Each lesion will be monitored for a period of 90 days or until it is cured, with the treatment being stopped if a lesion heals before the six-week mark. The study aims to determine the local efficacy of this intervention in managing the condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis

Exclusion Criteria:

* Immunocompromised
* Allergic reaction to treatment.

Where it's running

• Mustansiriyah University
  Baghdad, Iraq Recruiting

Study contacts

• Study coordinator: Hayder Adnan Fawzi, PhD
• Email: haider-pharm@almustafauniversity.edu.iq
• Phone: 07800106177

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ciprofloxacin injections for treating skin leishmaniasis

  This study is testing if ciprofloxacin injections can effectively treat skin leishmaniasis compared to the standard treatment with sodium stibogluconate.

  Recruiting Phase 2 Al-Mustafa University College · Baghdad · NCT06798402

• Using levofloxacin injections to treat skin leishmaniasis

  This study is testing if weekly injections of levofloxacin can effectively treat skin leishmaniasis in patients with localized lesions.

  Recruiting Phase 2 Al-Mustafa University College · Baghdad · NCT06797544

• Using thermotherapy at health centers to treat skin leishmaniasis in Ethiopia

  This study tests whether thermotherapy using the ThermoMed device can be feasibly used in primary care to treat cutaneous leishmaniasis in Ethiopia and sees how well it works for people in the Sodo area.

  Recruiting Armauer Hansen Research Institute, Ethiopia · Addis Ababa · NCT06746350

• Immunogenicity screening of Leishmania vaccine candidate antigens in Ethiopian patients

  This study tests whether six Leishmania vaccine candidate antigens can trigger T-cell responses in patients with cutaneous or visceral leishmaniasis.

  Recruiting at 2 sites Institute of Tropical Medicine, Belgium · Addis Ababa and 1 other locations · NCT07783243

• Pediatric leishmaniasis in Italy: clinical and treatment patterns

  This project will collect medical information to see how leishmaniasis presents and is treated in children under 18 in Italy.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Tuscany · NCT07504757

• Arnica tincture for treating cutaneous leishmaniasis

  This test will see if applying arnica tincture to skin lesions helps heal cutaneous leishmaniasis in people aged 12 and older.

  Recruiting Phase 3 Universidad de Antioquia · Medellín, Antioquia · NCT06822478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.